Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7081 to 7095 of 7707 results

  1. Apremilast for treating active psoriatic arthritis (TA372)

    This guidance has been updated and replaced by NICE technology appraisal guidance 433.

    Technology appraisal guidance
    Published
    16 December 2015

  2. Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)

    This guidance has been updated and replaced by NICE technology appraisal guidance 898.

    Technology appraisal guidance
    Published
    27 February 2019

  3. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (TA567)

    This guidance has been updated and replaced by NICE technology appraisal guidance 933. People already having tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies through the Cancer Drugs Fund can continue. For those people, it will be funded by the company until they and their NHS clinician consider it appropriate to stop.

    Technology appraisal guidance
    Published
    13 March 2019

  4. The clinical effectiveness and cost effectiveness of insulin pump therapy (TA57)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 151.

    Technology appraisal guidance
    Published
    26 February 2003

  5. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

    This guidance has been updated and replaced by NICE technology appraisal guidance 524.

    Technology appraisal guidance
    Published
    28 June 2017

  6. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)

    This guidance has been updated and replaced by NICE technology appraisal guidance 531.

    Technology appraisal guidance
    Published
    28 June 2017

  7. Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (TA45)

    This guidance has been updated and replaced by NICE technology appraisal guidance 91.

    Technology appraisal guidance
    Published
    19 July 2002

  8. Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

    This guidance has been updated and replaced by NICE technology appraisal guidance 849.

    Technology appraisal guidance
    Published
    24 May 2019

  9. Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)

    This guidance has been updated and replaced by NICE technology appraisal guidance 766.

    Technology appraisal guidance
    Published
    19 December 2018

  10. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA557)

    This guidance has been updated and replaced by NICE technology appraisal guidance 683.

    Technology appraisal guidance
    Published
    10 January 2019

  11. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA872.

    Technology appraisal guidance
    Published
    23 January 2019

  12. The clinical effectiveness and cost effectiveness of tension-free vaginal tape for stress incontinence (TA56)

    This guidance has been updated and replaced by NICE guideline CG40. [Replaced by NICE guideline CG171 (September 2013)] 

    Technology appraisal guidance
    Published
    26 February 2003

  13. Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)

    This guidance has been updated and replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    13 December 2002

  14. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA573)

    This guidance has been updated and replaced by NICE technology appraisal guidance 897.

    Technology appraisal guidance
    Published
    10 April 2019

  15. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA578)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA798.

    Technology appraisal guidance
    Published
    1 May 2019